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Role of Reflex Sympathetic Withdrawal in the Hemodynamic Response
to an Increased Inotropic State in Patients With Severe Heart Failure
J. MALCOLM O. ARNOLD, MD, PAUL L. LUDMER, MD, RICHARD F. WRIGHT, MD,
PETER GANZ, MD, EUGENE BRAUNWALD, MD, FACC, WILSON S. COLUCCI, MD
Boston. Massachusetts
Newer positive inotropic agents used in the treatment of
severe heart failure not only increase cardiac contrac-
tility, but also cause peripheral vasodilation. It is not
known to what extent this vasodilation is due to a direct
peripheral action of the drug, as opposed to reflex with-
drawal of sympathetic tone secondary to an augmented
inotropic state. In 16 patients with severe heart fallure,
a 48 hour intravenous infusion of milrinone, a positive
inotropic vasodilator drug, resulted In an increase in
stroke volume index from 26 ± 2 to 34 ± 3 ml/m"
(p < 0.001), a reduction in forearm vascular resistance
measured by venous plethysmography from 43 ± 5 to
27 ± 3 U (p < 0.003) and an increase in forearm venous
capacitance from 2.1 ± 0.2 to 2.9 ± 0.2 ml/lOO ml
(p < 0.001).
To determine whether a withdrawal of sympathetic
tone contributed to this vasodilation, milrinone was in-
fused directly into the left main coronary artery in eight
of the patients, thereby eliminating any direct vascular
effects of the drug. Intracoronary milrinone (50 ILg/min)
caused an increase in peak positive first derivative of
Several potent new positive inotropic agents including am-
rinone, milrinone, MDL-17,043 and MDL-19,205 have been
developed, and are undergoing hemodynamic and clinical
evaluation in patients with severe congestive heart failure
(I). Although these agents markedly increase contractile
force in isolated myocardium, in many cases they also exert
a direct vasodilating effect on isolated vascular smooth mus-
cle (2.3), thereby bringing into question the mechanism by
which they cause hemodynamic effects in humans. Indeed.
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pressure (658 ± 49 to 784 ± 68 mm Hg/s; p < 0.01)
and stroke volume index (20 ± 2 to 25 ± 3 ml/m"; p <
0.0001), which was associated with a reduction in plasma
norepinephrine from 540 ± 101 to 423 ± 90 pg/ml
(p < 0.01). There was a small, statistically insignificant
decrease in forearm vascular resistance from 49 ± 5 to
44 ± 9 U (p = NS), and a small, insignificant increase
in forearm venous capacitance from 1.6 ± 0.3 to 2.0 ±
0.4 ml/l00 ml (p = 0.05). Intravenous administration
of milrinone after intracoronary infusion caused a com-
parable reduction in plasma norepinephrine to 452 ±
75 pg/ml, but in contrast to intracoronary administra-
tion, caused a 49% reduction in forearm vascular re-
sistance (p < 0.03) and a 63% increase in forearm venous
capacitance (p < 0.01).
Thus, systemic vasodilation with milrinone is due pri-
marily to a direct peripheral effect of systemic drug.
Although intracoronary milrinone infusion was associ-
ated with withdrawal of sympathetic tone, this appeared
to cause little, if any, significant systemic vasodilation.
(J Am Coli Cardiol 1986;8:413-8)
it has been claimed that amrinone, the only agent in this
class with approval for clinical use, acts entirely as a vaso-
dilator and that the observed improvement in myocardial
function results from this action (4). In the case of milrinone,
we previously demonstrated (5,6) in humans that both an
increase in myocardial inotropic state and systemic vaso-
dilation contribute significantly to the hemodynamic effects
of the drug. However. it is not known to what extent this
vasodilation is caused by a direct effect of the drug on the
vascular bed or by an indirect reflex withdrawal of sym-
pathetic tone due to improved cardiac pump function. It has
been suggested that the latter occurs with the administration
of digitalis glycosides, which are positive inotropic agents
that have a direct vasoconstrictor action (7).
The purpose of this study was to determine whether the
intravenous administration of milrinone results in peripheral
arterial or venous dilation. or both, and if so, to test the
hypothesis that a significant portion of this vasodilation is
0735-1097/86/$3.50
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due to withdrawal of sympathetic tone . Forearm plethys-
mography was used to compare directly the vascular effects
of milrinone infused systemically or into the left main coro-
nary artery , so that any direct peripheral vascular effects of
the drug could be eliminated.
Methods
Study patients. The study was approved by the Com-
mittee for the Protection of Human Subjects from Research
Risks of the Brigham and Women's Hospital (April 16,
1984) and all patients gave written informed consent. Six-
teen patients (14 male, 2 female; average age, 56 ± 3 years)
with congestive heart failure of New York Heart Association
functional class III (n = 6) or IV (n == 10) were studied.
Heart failure was secondary to ischemic heart disease in II
and idiopathic dilated cardiomyopathy in 5. Baseline mean
left ventricular ejection fraction measured by radionuclide
gated blood pool imaging within 48 hours of study entry
was 15 ± 2% .
All 16 patients received a continuous 48 hour intravenous
infusion of milrinone . In eight of these patients, milrinone
was also infused directly into the left main coronary artery
(as described later) in the 24 to 48 hours preceding the
intravenous study. The hemodynamic effects of intracoro-
nary milrinone infusion were reported in detail in an earlier
study in a group of II patients, which included the 8 patients
reported in this study (6).
Intracoronary infusion protocol. All vasodilators were
stopped at least 48 hours before study, and digoxin and
diuretics were withheld on the morning of the study. A
balloon-tipped, flow-directed pulmonary artery catheter with
a proximal right atrial port was advanced into the distal
pulmonary artery through a 7F Cordis sheath in the right
internal jugular or subclavian vein . An 8F micromanometer-
tipped pigtail catheter (Mikro-tip, Millar Instrument Inc.)
was advanced to the tip of the left ventricle through a 9F
Cordis side aim sheath in the right femoral artery and cal-
ibrated externally against a mercury reference with simul-
taneous matching to the left ventricular luminal pressure.
The first time derivative of left ventricular pressure (peak
positive first derivative of pressure [dP/dt]) was determined
by electronic differentiation (Electronics for Medicine). A
7F L4 Judkins catheter was advanced into the ostium of the
left main coronary artery through an 8F Cordis sheath in
the left femoral artery. Contrast medium (Hypaque 76,5 to
10 ml) was injected into the left main coronary artery to
confirm that there was no significant left main coronary
artery disease.
Cardiac output was measured by the Fick method as
oxygen consumption divided by the difference between fem-
oral and pulmonary artery oxygen contents. Oxygen con-
sumption was measured using an oxygen consumption mon-
itor (MRM-2, Waters Instruments Inc.). Other hemodynamic
variables were measured as the mean of at least 15 consec-
utive cardiac cycles . Systemic vascular resistance was cal-
culated as (mean arterial pressure - mean right atrial pres-
sure) x 80/cardiac output. Stroke volume index was calculated
as cardiac index/heart rate. Blood samples for plasma nor-
epinephrine concentration were drawn from the femoral ar-
tery and placed in chilled test tubes containing reduced
glutathione in ethyleneglycol tetraacetic acid, placed on ice,
centrifuged and stored at - 70°C until measured by a ra-
dioenzymatic technique (8) .
Forearm blood flow was measured by venous plethys-
mography using a mercury in rubber strain gauge (9) with
a venous occluding pressure of 40 mm Hg. A wrist cuff
was inflated to 200 mm Hg I minute before each recording,
and the mean of 6 to 10 flows was calculated at each mea-
surement point. Forearm vascular resistance was calculated
as mean arterial pressure/forearm blood flow and expressed
in units . Forearm venous capacitance was measured by an
equilibration technique with the venous cuff inflated to 30
mm Hg for 2 minutes, as previously described (7).
After baseline measurements of hemodynamics and nor-
epinephrine were completed, 5% dextrose in water , the ve-
hicle for milrinone, was infused into the left main coronary
artery at a rate of 4 mllmin. To confirm adequate perfusion
of the myocardium and sufficient contractile reserve , do-
butamine (2.5 to 200 JLg/min) was then infused into the left
main coronary artery . All patients showed an increase in
positive dP/dt with intracoronary dobutamine. After the do-
butamine infusion, hemodynamic variables were allowed to
return to baseline (20 to 30 minutes) . The baseline for mil-
rinone infusion was determined during repeat intracoronary
infusion of 5% dextrose in water and did not differ from
initial baseline values. Intracoronary infusion of milrinone
was then performed at progressively increasing rates of 1.5
to 400 p.g/min. Each infusion rate was maintained for 6
minutes , and measurements, including plasma milrinone
and serum norepinephrine concentrations, were made during
the last 4 minutes at each infusion rate . Because all patients
received milrinone infusions of at least 50 JLg/min, this rate
was chosen for statistical comparison with control values
during infusion of 5% dextrose in water. Plasma milrinone
concentration at the end of the 50 p.g/min infusion period
averaged 55 ± 6 ng/m!.
After the intracoronary infusion of milrinone, a brief
intravenous infusion (75 p.g/kg) of milrinone was admin -
istered over I minute, and hemodynamic measurements were
repeated 7 to 9 minutes later, at which time the plasma
milrinone concentration was 428 ± 48 ng/m!.
Prolonged 48 hour intravenous milrinone infusion
protocol. Vasodilator therapy was discontinued at least 48
hours before intravenous milrinone administration. All pa-
tients were taking digoxin, the dose of which was held
constant during the study. The dose of diuretic was adjusted,
if necessary, to manage clinically significant changes in fluid
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balance . During the 24 hours before drug administration, a
balloon-tipped, flow-directed thermodilution catheter with
a proximal opening in the right atrium was advanced under
fluoroscopic guidance into the distal pulmonary artery through
a 7F Cordis sheath in the right internal jugular or subclavian
vein. A Teflon cannula was inserted percutaneously into the
radial artery . Routine measurements were made and cardiac
output was determined by thermodilution (Instrumentation
Laboratory, Inc. 70 I or American Edwards Laboratory
9520A) .
Milrinone was diluted in 5% dextrose in water and ad-
ministered through the right atrial port of the central catheter
as a bolus injection (50 /Lg/kg) over 10 minutes followed
by continuous infusion (0.25 or 0.5 /Lg/kg per min) for 6
hours. After 6 hours, all patients received 0.5 /Lg/kg per
min until the end of the infusion (48 hours). Hemodynamic
measurements were made before infusion as two sets of
control measurements separated by at least 10 minutes and
differing by less than 10%; at 5, IS, 30, 45 , 60 and 180
minutes , and then every 6 hours to the termination of the
infusion . Forearm plethysmography was performed twice
during the baseline period , separated by at least 10 minutes,
and at 24 and 48 hours of infusion . In 13 patients , the steady
state plasma milrinone concentration was measured during
the second 24 hours of infusion (10), at which time the
mean plasma milrinone concentration in the patients who
received 0 .25 /Lglkg per min during the first 6 hours (162
± 18 ng/ml ; n = 7) did not differ significantly from that
in patients who received 0.5 /Lg/kg per min (173 ± 28
ng/ml; n = 6). Therefore , at 24 to 48 hours, hemodynamic
changes from control are considered for all 16 patient s to-
gether.
Statistical analysis. In the intracoronary study, results
were compared with the control infusion of 5% dextrose in
water. In the 48 hour intravenous infusion study, the mean
of all hemodynamic and plethysmographic determinations
obtained from 24 to 48 hours was compared with the mean
of the two baseline determinations . Comparisons were made
using Student's t test for paired data . When more than two
observations were compared, the data were subjected to
analysis of variance , and significant differences were de-
termined by Bonferroni 's method as those achieving a prob-
ability (p) value of less than 0 .05/n , where n is the number
of observations compared (II ). Results are expressed as the
mean ± SEM .
Results
Hemodynamic, vascular and reflex sympathetic ef-
fects of intracoronary milrinone infusion. There were no
changes in mean arterial pressure (5% dextrose in water
[05 W], 72 ± 2 mm Hg; milrinone, 71 ± 2 mm Hg; p =
NS) or systemic vascular resistance (05W, 1,587 ± 150
dynes-s-crn " "; milrinone, 1,500 ± 141 dynes-scm t "; p =
NS) with the intracoronary infusion of milrinone (50 /Lg/min).
Peak positive dP/dt increased from 658 ± 49 to 784 ± 68
mm Hg/s (p < 0 .01), cardiac index from 2.0 ± 0.1 to 2.2
± 0.1 liters/min per rrr' (p < 0.0 I) and stroke volume index
from 20 ± 2 to 25 ± 3 rnl/rrr' (p < 0.001). Pulse pressure
increased from 38 ± 3 to 42 ± 3 mm Hg (p < 0.005) .
Left ventricular end-diastolic pressure decreased from 29 ±
2 to 24 ± 2 mm Hg (p < 0 .017) and right atrial pressure
from 12 ± 2t09 ± 2mmHg (p <0.017).
Intracoronary milrinon e infusion (50 uglmin] caused a
decrease in plasma norepinephrine from 540 ± 101 to 423
± 90 pg/ml (p < 0.01). This was associated with a small
but consistent decrease in heart rate from 93 ± 7 to 90 ±
7 beats/min (p < 0.017). Intracoronary infusion was as-
sociated with a decrease in forearm vascular resistance from
49 ± 5 to 44 ± 9 U (p = 0.36), and an increase in forearm
venous capacitance from 1.6 ± 0.3 to 2.0 ± 0.4 mlllOO
ml (p = 0.05) .
Comparative hemodynamic and vascular effects of
intracoronary and brief intravenous milrinone infusion
(Fig. 1). Compared with intracoronary (i.e. ) infusion of
milrinone, brief intravenous (i.v.) infusion caused signifi-
cantly larger decreases in systemic vascular resistance (i.e .,
87 ± 136; i.v ., 640 ± 77 dynes.s.cm- 5; p < 0 .003), mean
arterial pressure (i.c ., I ± I ; i.v . , 10 ± 3 mm Hg; p <
0.003) and mean right atrial pressure (i.c . , 3 ± 1; i.v.,
7 ± 1 mm Hg; p < 0 .001) . Despite comparable decreases
in plasma norepinephrine and similar increases in positive
dp/dt (i.c . , 127 ± 24;i .v . , 214 ± 43 mmHgls;p = NS),
intravenous milrinone was associated with a larger reduction
in forearm vascular resistan ce , and a larger increase in fore-
arm venous capacitance when compared with intracoronary
milrinone (Fig. I).
Hemodynamic and peripheral vascular effects of pro-
longed 48 hour intravenous milrinone infusion (Fig. 2).
After 24 hours of intravenous milrinone infusion, the cardiac
index had increased from 2.2 ± 0.2 to 2.9 ± 0.2 liters/min
per m2 (p < 0.001) because of a small increase in heart rate
from 86 ± 3 to 89 ± 4 beats/min (p < 0.04) and a larger
increase in stroke volume index from 26 ± 2 to 34 ± 3
ml/rrr' (p < 0.001). There were small decreases in mean
pulmonary capillary wedge pressure (24 ± 1 to 20 ± I
mm Hg; p < 0 .04) and right atrial pressure (9 ± 2 to 7 ±
I mm Hg; p = 0 .07). Although mean arterial pressure was
not changed significantly (control, 71 ± 3; milrinone, 73
± 2 mm Hg), systemic vascular resistance was significantly
decreased from 1,326 ± 153 to 1.056 ± 76 dynes-s-cm"?
(p < 0 .03) .
Forearm plethysmography indicated a marked 74% in-
crease in forearm blood flow ( 1.9 ± 0 .2 to 3.3 ± 0 .3
mlllOO ml per min; p < 0.001) , and a 37% decrease in
calculated forearm vascular resistance from 43 ± 5 to 27
± 3 U (p < 0.003). Forearm venous capacitance increased
38% from 2.1 ± 0.2 to 2.9 ± 0.2 mil100 ml (p < 0.001).
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Figure 1. Comparativeeffects of acute intracoronary
(i.e., 50 JLg/min) and intravenous (i.v., 75 p,g/kg)
milrinone administration on plasma norepinephrine
concentration and forearm hemodynamics in eight
patients. A, Plasma norepinephrine concentration,
forearm blood flow and mean arterial pressure. B.
Forearmvascular resistance and venous capacitance.
Significant differences among the three conditions
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Figure 2. Effect of 48 hour intravenousinfusionof milrinone(i.v.
Mil) (0.5 JLg/kg per min) on forearm blood flow, vascular resis-
tance and venous capacitance determined by plethysmography in
16 patients with severe heart failure.
may also cause dilation of peripheral blood vessels as a
result of reflex withdrawal of sympathetic tone. Although
reflex withdrawal of vasoconstrictor tone during the treat-
ment of patients with heart failure has often been alluded
to, there is little direct evidence of its occurrence because
of the difficulty of distinguishing direct from indirect drug
effects on the vasculature in intact humans. Mason and
Braunwald (7) demonstrated contrasting effects of ouabain
on the vasculature of normal subjects, in whom the drug
caused arterial and venous constriction, and in patients with
heart failure, in whom it caused vasodilation that was at-
tributed to a withdrawal of sympathetic tone secondary to
an improvement in pump function. Subsequent studies in
humans (15) suggested that this action of digitalis may be
mediated primarily through sensitization of myocardial re-
ceptors rather than an improvement in pump function.
Peripheral vascular effects of intravenous versus
intracoronary milrinone. Plethysmographic assessment of
forearm blood flow and venous capacitance and calculation
of forearm vascular resistance in the present study provide
direct evidence for previous suggestions (5,6,16,17) that
intravenous administration of milrinone reduces peripheral
vascular resistance and increases peripheral venous capac-
itance. This effect occurred after the intravenous bolus in-
jection, which resulted in a relatively high plasma concen-
tration of 428 ± 48 ng/ml, and during a 48 hour steady
state infusion which resulted in a plasma concentration ofO'--:BLas-erlinLe- ivMilBaseline iv Mil
Forearm Blood Forearm Vascular Forearm Venous
Flow 50 Resistance 5 Copacttonce5
~p<OOO\~ -p<OOO3~ ~p<OOO\-
c:: 4 40 4
~ ~~ 3 .~ 30 ~ 3~ s ~~ 2 20 E: 2
Discussion
In patients with severe congestive heart failure there is
a generalized increase in sympathetic outflow and circulat-
ing catecholamines (12). This results in pronounced vaso-
constriction in the renal, splanchnic, muscle and cutaneous
circulations which may result in further cardiac dysfunction.
Drugs that dilate peripheral vessels directly have therefore
been used successfully in the treatment of congestive heart
failure (13,14).
It is possible that directly acting positive inotropic agents
JACCVol. 8, No.2
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approximately 165 ng/ml, a drug level that is commonly
achieved during oral drug therapy (18).
The observation that intracoronary milrinone causes only
a small degree of arterial and venous dilation in the forearms
of patients receiving digoxin demonstrates that, in patients
with cardiac failure, a modest increase in inotropic state in
itself causes little, if any, significant reflex peripheral vaso-
dilation. Nevertheless, a small degree of withdrawal of sym-
pathetic tone did appear to occur because both plasma nor-
epinephrine and heart rate were significantly reduced with
intracoronary drug administration. It is possible that there
was a preferential withdrawal of cardiac sympathetic tone,
or that the observed trend for a reduction in forearm vascular
resistance might have been significant with a larger number
of patients. Although these data do not exclude the possi-
bility that an increase in inotropic state can result in a small
degree of peripheral vasodilation, it is clear that in the case
of milrinone given to patients already receiving digoxin,
this effect is of considerably less hemodynamic importance
than the direct vasodilator action of the drug. These data
are consistent with the recent observation by Cody et a!.
(19) thai the infusion of milrinone directly into the isolated
human forearm results in marked arterial dilation, and they
support the suggestion that at least some of vasodilator prop-
erties of milrinone are independent of the positive inotropic
actions of the drug.
Limitations. A limitation to the interpretation of this
study is that the intracoronary infusion of milrinone at a rate
of 50 j.tg/min resulted in significant accumulation of mil-
rinone in the systemic circulation with an average plasma
concentration of approximately 55 ng/ml. In a previous study
(5) we observed no significant effect on systemic vascular
resistance after an intravenous milrinone injection that re-
sulted in a plasma level of 63 ± 4 ng/m!. Nevertheless, we
cannot exclude the possibility that some or all of the minor
changes in forearm vascular resistance and venous capaci-
tance during intracoronary drug infusion of milrinone were
due to a direct effect on the peripheral circulation.
Mechanism of sympathetic withdrawal. The mecha-
nism by which milrinone resulted in sympathetic withdrawal
cannot be determined from these data. Another inotropic
agent, digitalis, is known to augment the tonic inhibitory
influence on the vasomotor center in dogs when applied to
the epicardium (20,21) or when administered by intracor-
onary (22) or long-term intravenous injection (23). Like-
wise, intravenous administration of a digitalis glycoside to
patients with left ventricular dysfunction caused a reduction
in forearm vascular resistance at rest and a normalization
of the baroreflex-rnediated vasoconstrictor response to lower
body negative pressure (24). These studies have suggested
that digitalis may cause a direct sensitization of myocardial
baroreceptors. It is not known whether milrinone can also
exert such a sensitizing effect. Because all of the patients
in this study were receiving digitalis, such an action of
milrinone would have been superimposed on that of digitalis
and, therefore, may not have been apparent.
Theoretically, positive inotropic agents could cause re-
flex withdrawal of sympathetic tone as a result of their
hemodynamic effects acting on vascular baroreceptors, car-
diac low pressure or intramyocardial receptors (25). In the
present study, mean arterial pressure was not altered with
intracoronary milrinone and the increase in pulse pressure
was small, so it is unlikely that arterial baroreceptors were
activated. Furthermore, the reduction in arterial pressure
with intravenous milrinone should have increased rather
than decreased sympathetic activity. Intramyocardial recep-
tors with unmyelinated vagal afferents are important in al-
tering peripheral vascular tone in patients with cardiac fail-
ure (15), an increase in receptor discharge reducing efferent
sympathetic activity. Although the specific hemodynamic
changes that stimulate these intramyocardial receptors are
not known, receptor discharge increases both with an in-
crease in left ventricular end-diastolic pressure and during
systolic contraction (26,27). Although milrinone decreased
left ventricular end-diastolic pressure, there was a definite
increase in cardiac contractility; thus, milrinone theoreti-
cally could have resulted in a withdrawal of sympathetic
tone through this mechanism.
Conclusions. Systemically administered milrinone caused
marked dilation of peripheral arteries and veins in patients
with severe congestive heart failure. Comparison of the
peripheral vascular effects of systemic and intracoronary
milrinone administration indicates that this peripheral vaso-
dilator effect was due primarily to direct vascular actions
of the drug. Although there appears to be a reduction in
sympathetic tone during intracoronary milrinone infusion,
little, if any peripheral vasodilation can be attributed to this
mechanism.
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